Keywords: falling, profit, low, sales, amgen, first-quarter, weighed
Falling profit on low sales for Amgen
Article | 27 April 2009
Amgen's first-quarter profit was weighed down by declining sales of highest-earning product Aranesp (darbepoetin alfa), falling 7% year-on-year.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
